Abstract
Following reports of increased new-onset diabetes and worse severity of DKA for children with diabetes following SARS-CoV-2 infection, we studied hospitalization rates for children with type 1 diabetes (T1DM) and type 2 diabetes (T2DM) in our center during the citywide shutdown. Methods. We conducted a retrospective chart review of children admitted to our two hospitals from January 1, 2018, to December 31, 2020. We included ICD-10 codes for diabetic ketoacidosis (DKA), hyperglycemic hyperosmolar syndrome (HHS), and hyperglycemia only. Results. We included 132 patients with 214 hospitalizations: 157 T1DM, 41 T2DM, and 16 others (14 steroid induced, 2 MODY). Overall admissions rates for patients with all types of diabetes were 3.08% in 2018 to 3.54% in 2019 (p = 0.0120) and 4.73% in 2020 (p = 0.0772). Although there was no increase of T1DM admissions across all 3 years, T2DM admission rates increased from 0.29% to 1.47% (p = 0.0056). Newly diagnosed T1DM rates increased from 0.34% in 2018 to 1.28% (p = 0.002) in 2020, and new-onset T2DM rates also increased from 0.14% in 2018 to 0.9% in 2020 (p = 0.0012). Rates of new-onset diabetes presenting with DKA increased from 0.24% in 2018 to 0.96% in 2020 (p = 0.0014). HHS increased from 0.1% in 2018 to 0.45% in 2020 (p = 0.044). The severity of DKA in newly diagnosed was unaffected (p = 0.1582). Only 3 patients tested positive for SARS-CoV-2 infection by PCR. Conclusion. Our urban medical center is located in Central Brooklyn and serves a majority who are Black. This is the first study investigating pediatric diabetes cases admitted to Brooklyn during the first wave of the pandemic. Despite the overall pediatric admissions declining in 2020 due to the citywide shutdown, overall hospitalization rates in children with T2DM and in new-onset T1DM and T2DM increased, which is not directly associated with active SARS-CoV-2 infection. More studies are needed to elucidate the reason for this observed increase in hospitalization rates.
1. Introduction
New York City (NYC) became an epicenter of the COVID-19 pandemic in March 2020, when the NYC Department of Health confirmed a total of 238,338 SARS-CoV-2 cases in NYC [1]. According to the NYC Department of Health, rates of SARS-CoV-2 cases and hospitalizations among children and adolescents ages 0-17 were 486.7 and 38.16 per 100,000 population during a pandemic, respectively [1]. Though these rates are low compared to older age categories, the CDC reported that children and adolescents with diabetes are at higher risk for severe COVID-19 disease [2].
The incidence of newly diagnosed diabetes continues to rise in the United States, with a 4.8% increase per year for type 2 diabetes (T2DM) and a 1.9% increase per year for type 1 diabetes mellitus (T1DM) between 2002 and 2015 [3]. The effect of SARS-CoV-2 infection may increase incidence of diabetes in children. Early on, as the first wave of the COVID-19 pandemic subsided, some have reported increased incidence of new-onset T1DM [3–9] and new-onset T2DM [6, 7, 10–12]. Initially, U.K. researchers noted an apparent rise of new-onset T1DM rates in children during the COVID-19 pandemic, with evidence of SARS-CoV-2 infection or exposure in a proportion of those tested [9]. Similarly, in the U.S., a recent single-center study discovered a 45% increase of new cases of T1DM [7]. Another U.S. study reported 15.2% rise of T1DM rates during the pandemic compared to prepandemic period, with non-Hispanic Blacks disproportionally affected over a three-year period [6].
Several researchers reported an increase of obesity risk factors and rates of obesity during lockdown and suggested that it may lead to metabolic decompensation, triggering the increase of T2DM [13–16]. Recent studies also found increased incidence and prevalence rates of presentation of T2DM [6, 11, 17–19]. One U.S. study found a significant rise of more than double the incidence (231%) of pediatric T2DM from 2019 to 2020 [7]. Interestingly, Marks et al. examined the variation by race and found that T2DM significantly increased during pandemic, with non-Hispanic Blacks (NHBs) disproportionally affected [6]. In contrast, Chao et al. found a steady rise in patients with new-onset T2DM, disproportionally affecting Hispanic youth (82%) [17].
In addition to the increasing cases, several authors reported the increase of risk and severity of diabetic ketoacidosis (DKA) for both T1DM and T2DM [3, 4, 6, 7, 9, 17, 20–23]. Though the exact cause is not known, it was suggested that delayed diagnosis of more than 30 days due to school closures may contribute to worsened severity of DKA [5, 24, 25]. In the U.K., authors emphasized that over half of children (52%) presented with severe DKA [9]. Recently, a meta-analysis examining the incidence of DKA in pediatric patients with T1DM concluded that compared to prepandemic, there was a 35% higher risk of DKA postpandemic (RR 1.35, 95% CI 1.2-1.35) and a 75% increased risk for severe DKA in T1DM (RR 1.76, 95% CI 1.33-2.33) [4]. Similarly, Marks et al. found not only increased rates of DKA in T1DM but also increased rates of severe DKA postpandemic [6]. In particular, NHB youth and boys had higher rates of incident T1DM during the pandemic than in the preceding two years [6]. A similar trend of increased DKA or DKA with hyperosmolality and severe DKA was observed in those with T2DM [6, 11, 17].
Racial disparities have contributed to poor outcomes in SARS-CoV-2 infection among NHB and Hispanic population; however, data on the incidence of new onset of T1DM and T2DM and variation by race, age, and severity of presentation in NHB youth in urban settings are not well studied. SUNY Downstate Health Sciences University and NYC H+H/Kings County are located in Central Brooklyn serving inner-city children and youth; therefore, data regarding diabetes admissions and severity of presentation during the COVID-19 pandemic is needed. In addition, we took into account how the “COVID-19-only” designation at SUNY Downstate Health Sciences University affected hospital admissions. We hypothesized that there is an increased rate of hospitalization of children and adolescents with T1DM and T2DM in 2020 during the COVID-19 pandemic compared to 2018 and 2019. The main objective of our study is to examine whether there is an increase in hospitalization rates and severity of presentation (DKA or HHS) and their risk factors of pediatric patients with T1DM and T2DM in our two hospital sites from 2018 to 2020 due to the COVID-19 pandemic.
2. Methods
2.1. Study Design
We conducted a retrospective chart review examining admission rates of patients with diabetes admitted for DKA, hyperglycemic hyperosmolar syndrome (HHS), or hyperglycemia to the SUNY Downstate Health Sciences University and NYC H+H Hospital/Kings County Hospital from January 1, 2018, to December 31, 2020, using ICD-10 diagnostic codes for T1DM, T2DM, HHS, mixed DKA/HHA, and hyperglycemia.
Our sites serve predominantly Black and Caribbean population, with about 20% living below poverty level [26]. Considering how COVID-19 pandemic affected our hospital admissions due to the NYC shutdown in 2020 and our academic institution SUNY Downstate being designed as COVID-19-only in 2020, we examined proportion of diabetic pediatric admissions to general pediatric admissions. Institutional Review Board (IRB) approval was obtained for this study (IRB protocol 1675462). They supervise all research in our institution and ensure that human research is ethical and valid.
2.2. Data Collection
We included children and adolescents ages 2-21 years old who were admitted to SUNY or Kings County for treatment of type 1 and type 2 diabetes mellitus for DKA, hyperglycemic hyperosmolar syndrome (HHS), or hyperglycemia from January 1, 2018, to December 31, 2020. We excluded those who did not meet inclusion criteria. Patients were all admitted for new-onset stabilization and diabetes education, presenting either with hyperglycemia or DKA or HHS, or are established patients with known T1DM or T2DM, and other types of DM requiring further management for hyperglycemic emergencies.
2.3. Variables
The diagnosis of T1DM was confirmed by presence of antibodies (GAD65, insulin antibodies, islet cell antibodies, and/or zinc transporter 8 antibodies) as markers of autoimmune β-cell destruction that usually leads to absolute insulin deficiency [27]. T2DM was diagnosed in patients without autoantibodies, with obesity and signs of insulin resistance [28].
We applied the diagnostic criteria for diabetes mellitus recommended by American Diabetes Association [28]. Patient were diagnosed if fasting plasma glucose (FPG) ≥ 126 mg/dL (7.0 mmol/L), or 2-hour plasma glucose ≥ 200 mg/dL (11.1 mmol/L) during oral glucose tolerance test or randomly in patients with classic symptoms of hyperglycemia [28].
We applied the International Society for Pediatric and Adolescent Diabetes (ISPAD) biochemical criteria for the diagnosis of diabetic ketoacidosis (DKA) comprised of hyperglycemia (blood glucose > 11 mmol/L (≈200 mg/dL)), venous pH < 7.3, and serum bicarbonate < 15 mmol/L, with ketonemia or ketonuria [29], and DKA severity as severe DKA (pH < 7.1, serum bicarbonate < 5 mmol/L), moderate DKA (pH 7.1-7.19, serum bicarbonate < 10 mmol/L), or mild DKA (pH 7.2-7.3, serum bicarbonate < 15 mmol/L) [29]. Diagnostic criteria for HHS comprised of plasma glucose concentration > 33.3 mmol/L (600 mg/dL), venous pH > 7.25 or arterial pH > 7.30, serum bicarbonate > 15 mmol/L, small ketonuria, absent to mild ketonemia, and effective serum osmolality > 320 mOsm/kg [29].
When serum osmolality was not measured, it was calculated based upon the calculation serum osmolality (mmol/kg): [2 × Na+] + [BUN/2.8] + [glucose/18]).
Variables used in these analyses included date of service, age in years, sex, race, ethnicity, anthropometrics, vital signs, and clinical characteristics including diagnosis of T1DM or T2DM or other type (MODY or steroid induced), complications such as DKA, HHS, hyperglycemia, new-onset or known diabetes, medications, length of PICU stay and inpatient floor stay, time to resolution of DKA or HHS, A1C, venous or arterial blood gases, urine and serum osmolality, chemistries, and evidence of current SARS-CoV-2 infection (PCR results). All patients were tested for SARS-CoV-2 infection in the emergency room regardless of symptoms, which was hospital policy.
2.4. Statistical Analysis
We applied descriptive statistics and summarized continuous variables using mean and standard deviation. We applied t-test with Bonferroni's adjustments for multiple testing. Categorical variables were analyzed using frequencies and percentages, and comparisons were made using a chi-squared test or Fisher's exact test. We set alpha to 0.05 for significance.
During SARS-CoV-2 peak in March 2020, pediatric admissions were greatly decreased, especially to SUNY Downstate. We accounted for this by calculating admission rates as a proportion of cases of patients with diabetes admitted divided by total pediatric admissions to the hospital in one-year period (2018, 2019, or 2020). Admission rates were calculated as number of annual cases divided in number of annual admissions per 100 admitted patients. Rate ratio (RR) was calculated as the ratio of rates of two groups R1/R2 was calculated with their Poisson's 95% confidence interval and associated p value [30]. We stratified results by type of diabetes. We calculated the admissions rates by year 2018 and 2019 and compared the rates over time compared with the year of the pandemic (2020). Statistical analysis was conducted using SAS Institute Inc. (2013), Version 9.4.
3. Results
We included 132 patients with 214 hospitalizations: 157 T1DM, 41 T2DM, and 16 other (14 steroid induced, 2 MODY). In the two hospitals, there were 2078 admissions in 2018, there were 2146 admissions in 2019, and there were 1564 admissions of patients aged 2-21 in 2020.
3.1. Admission Rates
Overall diabetic admission rates increased from 3.08% in 2018 to 3.54% in 2019 and 4.73% in 2020, which was only significant between 2019 and 2020 (p = 0.012) (Table 1). However, by excluding steroid induced and MODY admissions, increases for T1DM and T2DM combined were significant between 2018 to 2020 and 2019 to 2020 (Table 1).
Table 1.
Hospitalization rates of children and adolescents with type 1 and type 2 diabetes mellitus in our center from 2018 to 2020 (prepandemic to pandemic).
| Year 2018 | Year 2019 | Compare 2018-2019 | Year 2020 | Compare 2018-2020 | Compare 2019-2020 | ||||
|---|---|---|---|---|---|---|---|---|---|
| N | Rate∗ (95% CI) | N | Rate (95% CI) | RR∗∗ (95% CI) p value |
N | Rate (95% CI) | RR (95% CI) p value |
RR (95% CI) p value |
|
| Type 1 DM (N = 157) | 52 | 2.50 (1.9-3.3) | 57 | 2.66 (2.0-3.4) | 1.06 (0.72-1.58) p = 0.76 |
48 | 3.07 (2.3-4.1) | 1.23 (0.81-1.85) p = 0.31 |
1.16 (0.77-1.73) p = 0.46 |
| Type 2 DM (N = 41) | 6 | 0.29 (0.1-0.6) | 12 | 0.56 (0.3-1.0) | 1.94 (0.67-6.23) p = 0.19 |
23 | 1.47 (0.9-2.2) | 5.09 (2.02-15.29) p = 0.0001 |
2.63 (1.26-5.80) p = 0.0056 |
| DKA (N = 129) | 37 | 1.78 (1.3-2.5) | 50 | 2.33 (1.7-3.1) | 1.31 (0.84-2.10) p = 0.22 |
42 | 2.69 (1.9-3.6) | 1.51 (0.95-2.41) p = 0.07 |
1.15 (0.75-1.80) p = 0.50 |
| New-onset DM (N = 63) | 11 | 0.53 (0.3-1.0) | 18 | 0.84 (0.5-1.3) | 1.58 (0.71-3.71) p = 0.23 |
34 | 2.17 (1.5-3.0) | 4.11 (2.03-8.99) p < 0.0001 |
2.59 (1.42-4.87) p = 0.0008 |
| New-onset T1DM (N = 32) | 7 | 0.34 (0.1-0.7) | 5 | 0.23 (0.1-0.54) | 0.69 (0.17-2.53) p = 0.54 |
20 | 1.28 (0.8-2.0) | 3.80 (1.54-10.63) p = 0.0013 |
5.49 (2.00 -18.71) p = 0.0002 |
| DKA new-onset T1DM (N = 16) | 4 | 0.19 (0.1-0.5) | 2 | 0.09 (0.01-0.3) | 0.48 (0.04-3.38) p = 0.43 |
10 | 0.64 (0.3-1.2) | 3.3216 1.001-14.51 p = 0.04 |
6.8606 (1.46-64.40) p = 0.005 |
| New-onset T2DM (N = 24) | 3 | 0.14 (0.03-0.4) | 11 | 0.51 (0.3-0.9) | 3.55 (0.94-19.82) p = 0.04 |
14 | 0.90 (0.5-1.5) | 6.20 1.73-33.65 p = 0.0012 |
1.75 (0.74-4.25) p = 0.17 |
| DKA new-onset type 2 (N = 8) | 1 | 0.05 (0.001-0.3) | 2 | 0.09 (0.01-0.3) | 1.94 (0.10-114) p = 0.64 |
5 | 0.32 (0.1-0.7) | 6.64 (0.74-314) p = 0.06 |
3.43 (0.56-36.02) p = 0.14 |
| New-onset DKA (N = 24) | 5 | 0.24 (0.1-0.6) | 4 | 0.19 (0.1-0.5) | 0.77 (0.15-3.60) p = 0.72 |
15 | 0.96 (0.5-1.6) | 3.99 (1.38-14.02) p = 0.0046 |
5.15 (1.64-21.30) p = 0.0014 |
| HHS/mixed (N = 12) | 2 | 0.10 (0.01-0.3) | 3 | 0.14 (0.03-0.4) | 1.45 (0.17-17.4) p = 0.71 |
7 | 0.45 (0.2-0.9) | 4.65 (0.89-45.9) p = 0.0444 |
3.20 (0.73-19.19) p = 0.0902 |
| Hyperglycemia (N = 73) | 25 | 1.20 (0.8-1.8) | 23 | 1.07 (0.7-1.6) | 0.89 (0.48 -1.64) p = 0.69 |
25 | 1.60 (1.0-2.4) | 1.33 (0.73-2.41) p = 0.32 |
1.49 (0.81-2.75) p = 0.17 |
| All T1DM and T2DM | 58 | 2.8 (2.1-3.6) | 69 | 3.2 (2.5-4.1) | 1.15 (0.80-1.66) p = 0.43 |
71 | 4.5 (3.5-5.7) | 1.6264 (1.13-2.34) p = 0.0060 |
1.41 (1.01-2.0) p = 0.0420 |
| All cases | 64 | 3.08 (2.4-3.9) | 76 | 3.54 (2.8-4.4) | 1.15 (0.81-1.63) p = 0.41 |
74 | 4.73 (3.7-5.9) | 1.54 (1.08-2.18) p = 0.0120 |
1.34 (0.96-1.86) p = 0.0772 |
| Total pediatric admissions | 2078 | 2146 | 1564 | ||||||
Rate∗: admission rate. RR∗∗: rate ratio.
Though there was no difference in total T1DM admissions across all 3 years, T2DM admission rates increased dramatically from 0.29% (CI% 0.1-0.6) in 2018 and 0.56% (95% CI 0.3-1.0) in 2019 to 1.47% (CI% 0.9-2.2) (p = 0.0056) in 2020. Despite lower total pediatric cases in 2020, many more patients (n = 23) were admitted in 2020 with T2DM compared with 2018 (n = 6) and 2019 (n = 12). In 2020, 14 admissions were due to new-onset T2DM and 5 were due to DKA and 7 had HHS/mixed diagnosis.
We observed that new-onset DM hospitalization rates in 2018 was 0.53% and in 2019 was 0.84% and increased significantly to 2.17% in 2020. In terms of cases, the number of patients with new-onset DM increased from 11 to 18 to 34 from 2018 to 2019 to 2020. This increase is due to observed increases in both T1DM and T2DM new-onset admissions.
Newly diagnosed T1DM rates significantly increased from 0.34% in 2018 to 1.28% in 2020 (p = 0.0013), and new-onset T2DM rates also increased from 0.14% in 2018 to 0.9% (p = 0.0012) in 2020.
New-onset diabetes presenting with DKA also was noted to increase from 0.24% in 2018 to 0.96% in 2020 (p = 0.0014). We had 24 patients with new-onset diabetes presented with DKA admitted over 3-year time period. Five (21%) with DKA in 2018, 4 (17%) with DKA in 2019, and 15 (62%) with DKA in 2020 were admitted, indicating a 3-fold increase of admissions in 2020. Within this new-onset group presenting in DKA, the majority was ultimately diagnosed with T1DM (n = 10) compared to T2DM (n = 5). HHS/mixed presentation increased from 0.1% to 0.14% to 0.45% in 2018, 2019, and 2020, respectively.
In 2020, we observed an increase in HHS/mixed DKA cases which were accounted for by new-onset diagnosis of DM (n = 5), in contrast to 1 admission in 2018-2019. In 2020, from 7 total admissions for HHS/mixed DKA, 4 admissions were for T2DM, compared to none in 2018-2019.
Only 3 patients tested positive for COVID-19 by PCR testing on admission. One case was admitted with HHS/mixed DKA and SARS-CoV-2 pneumonia, another was admitted with hyperglycemia due to T2DM and SARS-CoV-2 pneumonia, and the last case was admitted with severe DKA and found to be SARS-CoV-2 positive.
3.2. Demographic Characteristics of Type 1 Diabetes
From 2018 to 2020, patients with T1DM were majority females (68%), Black (87%), and non-Hispanic (87%). There were no differences in demographic characteristics between years (Table 2).
Table 2.
Demographic characteristics of children and adolescents with type 1 diabetes mellitus admitted during COVID-19 pandemic.
| Year 2018 | Year 2019 | Year 2020 | Total | p value | |||||
|---|---|---|---|---|---|---|---|---|---|
| N | % | N | % | N | % | N | % | ||
| Total | 52 | 33% | 57 | 36% | 48 | 31% | 157 | 100% | |
| Sex | |||||||||
| Female | 33 | 63% | 37 | 65% | 37 | 77% | 107 | 68% | 0.2771 |
| Male | 19 | 37% | 20 | 35% | 11 | 23% | 50 | 32% | |
| Race | |||||||||
| Black | 44 | 85% | 49 | 86% | 45 | 94% | 138 | 87% | 0.2849 |
| White | 7 | 13% | 8 | 14% | 2 | 12% | 17 | 11% | |
| Asian | 0 | 0% | 0 | 0% | 1 | 2% | 1 | 1% | |
| Unknown | 1 | 2% | 0 | 0% | 0 | 0% | 1 | 1% | |
| Ethnicity | |||||||||
| Hispanic | 7 | 4% | 7 | 4% | 3 | 2% | 17 | 10% | 0.4505 |
| Non-Hispanic | 43 | 83% | 49 | 86% | 45 | 94% | 137 | 87% | |
| Unknown | 2 | 1% | 1 | 1% | 0 | 0% | 3 | 3% | |
3.3. Clinical Characteristics of Patients with Type 1 Diabetes
In 2020, patients presented with more severe acidosis (lower serum bicarbonate) when compared to 2018 (Table 3). Patients in 2020 were younger than patients in 2019 (p = 0.01), however had lower respiratory rates and lower BUN, but similar BMI z-scores.
Table 3.
Clinical characteristics of children and adolescents with type 1 diabetes mellitus admitted during COVID-19 pandemic.
| Year 2018 | Year 2019 | Compare 2018-2019 | Year 2020 | Compare 2018-2020 | Compare 2019-2020 | |
|---|---|---|---|---|---|---|
| Mean (SD) | Mean (SD) | p value | Mean (SD) | p value | p value | |
| Age (years) | 13 (3.8) | 16 (3.8) | 0.0001 | 13.8 (4.7) | 0.34 | 0.01 |
| Length of hospitalization (days) | 3.7 (1.7) | 3.4 (1.5) | 0.32 | 3.6 (1.5) | 0.67 | 0.54 |
| Length of PICU stay (days)∗ | 1.5 (0.8) | 1.6 (0.7) | 0.40 | 1.4 (1.0) | 0.74 | 0.27 |
| Length of floor stay (days)∗∗ | 2.2 (1.3) | 1.9 (1.5) | 0.35 | 2.1 (1.4) | 0.62 | 0.68 |
| Duration of DKA (hours)∗∗∗ | 17.1 (10.0) | 16.8 (10) | 0.87 | 14.1 (7.2) | 0.13 | 0.99 |
| Anthropometrics | ||||||
| Weight (kg) | 50.0 (18.1) | 57.1 (15.9) | 0.03 | 49.8 (18.9) | 0.95 | 0.03 |
| Height (cm) | 153.6 (18.9) | 159.5 (26.2) | 0.18 | 151.8 (20.6) | 0.65 | 0.10 |
| BMI (kg/m2) | 20.4 (4.6) | 21.1 (3.1) | 0.40 | 23.3 (21.2) | 0.34 | 0.43 |
| BMI percentile (%) | 55.6 (31.9) | 56.9 (24.5) | 0.81 | 49.8 (32.7) | 0.38 | 0.22 |
| BMI z-score | 0.1 (1.2) | 0.1 (0.9) | 0.99 | -0.1 (1.6) | 0.50 | 0.44 |
| Vital signs | ||||||
| Heart rate (beat per min) | 116.4 (19.7) | 117.5 (18.2) | 0.75 | 115.8 (18.9) | 0.75 | 0.63 |
| Respiratory rate (breath per min) | 23.9 (7.)8) | 23.0 (5.7) | 0.47 | 20.8 (3.1) | 0.47 | 0.02 |
| Temperature (°F) | 98.4 (0.8) | 98.2 (0.7) | 0.15 | 98.5 (1.0) | 0.15 | 0.05 |
| Oxygen (%) | 99.2 (1.1) | 97.8 (13.1) | 0.45 | 99.2 (1.0) | 0.45 | 0.48 |
| Biochemistry | ||||||
| Glucose (mg/dL) | 488.2 (243) | 501.3 (201) | 0.76 | 545.4 (272) | 0.76 | 0.34 |
| Sodium (mmol/L) | 135.0 (4.4) | 132.9 (5.1) | 0.02 | 132.3 (4.8) | 0.02 | 0.54 |
| Potassium (mmol/L) | 5.3 (1.3) | 5.4 (1.5) | 0.69 | 5.2 (1.3) | 0.69 | 0.53 |
| Chloride (mmol/L) | 96.4 (9.3) | 95.3 (7.9) | 0.49 | 95.9 (6.6) | 0.49 | 0.68 |
| Bicarbonate (CO2) (mmol/L) | 13.4 (6.3) | 10.1 (6.4) | 0.02 | 12.7 (6.9) | 0.02 | 0.08 |
| BUN (mg/dL) | 18.6 (9.2) | 17.4 (6.8) | 0.42 | 14.8 (5.6) | 0.42 | 0.04 |
| Creatinine (mg/dL) | 1.0 (0.4) | 1.1 (0.4) | 0.16 | 1.0 (0.3) | 0.16 | 0.15 |
| Calcium (mg/dL) | 9.6 (2.2) | 9.7 (1.7) | 0.72 | 9.0 (3.0) | 0.72 | 0.12 |
| Phosphorus (mg/dL) | 5.1 (2.3) | 4.8 (2.2) | 0.65 | 4.8 (2.4) | 0.65 | 0.95 |
| Magnesium (mg/dL) | 2.3 (0.6) | 2.2 (0.4) | 0.81 | 2.2 (0.7) | 0.81 | 0.98 |
| HbA1c (%) | 12.1 (2.0) | 12.6 (2.2) | 0.24 | 13.1 (2.2) | 0.24 | 0.38 |
| Serum osmolality (mOsm/kg) | 312 (40) | 307 (20) | 0.37 | 307 (27) | 0.42 | 0.99 |
| Beta-hydroxybutyrate (BHOB) (mmol/L) | 5.3 (2.9) | 6.5 (3.3) | 0.08 | 5.6 (2.4) | 0.08 | 0.13 |
| Urine ketone | 83.5 (40.7) | 74.5 (17.4) | 0.11 | 67.2 (31.8) | 0.62 | 0.18 |
| Venous blood gas | ||||||
| pCO2 (mmHg) | 34.5 (10. 6) | 28.1 (10.8) | 0.0027 | 32.4 (9.9) | 0.00 | 0.04 |
| Bicarbonate (HCO3) (mmol/L) | 15.0 (6.9) | 12.1 (5.8) | 0.0214 | 14.8 (6.5) | 0.02 | 0.03 |
| pH | 7.21 (0.1) | 7.13 (0.2) | 0.0029 | 7.18 (0.2) | 0.35 | 0.09 |
Length of PICU stay (days)∗ was calculated only among cases who were managed in PICU. Length of floor stay (days)∗∗ was calculated only among cases who were managed on the floor. Duration of DKA (hours)∗∗∗ was calculated only among cases admitted with DKA.
3.4. Demographic Characteristics of Patients with Type 2 Diabetes
In contrast, patients admitted as T2DM mostly comprised of males (59%), with a majority of Black (95%) and non-Hispanic (95%) (Table 4).
Table 4.
Demographic characteristics of children and adolescents with type 2 diabetes mellitus admitted during COVID-19 pandemic.
| Year 2018 | Year 2019 | Year 2020 | Total | p value | |||||
|---|---|---|---|---|---|---|---|---|---|
| N | % | N | % | N | % | N | % | ||
| 6 | 15% | 12 | 29% | 23 | 56% | 41 | 100% | ||
| Sex | |||||||||
| Female | 2 | 33% | 7 | 58% | 8 | 35% | 17 | 41% | 0.3691 |
| Male | 4 | 67% | 5 | 42% | 15 | 65% | 24 | 59% | |
| Race | |||||||||
| Black | 5 | 83% | 12 | 100% | 22 | 96% | 39 | 95% | 0.2973 |
| White | 0 | 0 | 0 | 0 | |||||
| Asian | 1 | 17% | 0 | 0 | 1 | 4% | 2 | 5% | |
| Unknown | 0 | 0 | 0 | 0 | |||||
| Ethnicity | |||||||||
| Hispanic | 0 | 0 | 0 | 0 | |||||
| Non-Hispanic | 6 | 100% | 10 | 83% | 23 | 100% | 39 | 95% | 0.0788 |
| Unknown | 0 | 0 | 2 | 17% | 0 | 0% | 2 | 5% | |
3.5. Clinical Characteristics of Patients with Type 2 Diabetes
In 2020, patients were older and heavier (p = 0.034) and had higher HR (p = 0.01), higher glucose levels (p ≤ 0.001), and more severe acidosis (serum bicarbonate) (p = 0.04) compared to the previous years (Table 5). The degree of dehydration is also worse in 2020 given the higher creatinine levels. There was no difference in average A1C. Severity of DKA in newly diagnosed diabetes was unaffected (p = 0.1582) (data not shown).
Table 5.
Clinical characteristics of children and adolescents with type 2 diabetes mellitus admitted during COVID-19 pandemic.
| N | Year 2018 | Year 2019 | Compare 2018-2019 | Year 2020 | Compare 2018-2020 | Compare 2019-2020 |
|---|---|---|---|---|---|---|
| Mean (SD) | Mean (SD) | p value | Mean (SD) | p value | p value | |
| Age mean (years) | 13.2 (2.7) | 12.9 (3.4) | 0.87 | 15.8 (3.1) | 0.07 | 0.02 |
| Length of hospitalization (days) | 3.2 (0.8) | 3.2 (1.1) | 0.86 | 3.7 (2.0) | 0.56 | 0.35 |
| Length of PICU stay (days)∗ | 1.5 (0.7) | 1.0 (1.0) | 0.67 | 1.79 (1.3) | 0.78 | 0.59 |
| Length of floor stay (days)∗∗ | 2.3 (1.5) | 3.0 (1.1) | 0.38 | 2.3 (1.5) | 0.93 | 0.16 |
| Duration of DKA (hours)∗∗∗ | 13.5 (7.8) | 9.0 (0.0) | 0.33 | 22.0 (16.2) | 0.46 | 0.44 |
| Anthropometrics | ||||||
| Weight (kg) | 85.0 (43.2) | 86.1 (35.9) | 0.03 | 98.7 (31.8) | 0.95 | 0.03 |
| Height (cm) | 160.5 (15.9) | 164.2 16.4) | 0.18 | 161.2 (37.0) | 0.65 | 0.09 |
| BMI (kg/m2) | 31.6 (11.1) | 30.8 (7.5) | 0.86 | 34.6 (8.4) | 0.48 | 0.21 |
| BMI percentile (%) | 94.2 (8.6) | 95.4 (7.1) | 0.74 | 97.5 (3.3) | 0.15 | 0.26 |
| BMI z-score | 2.0 (0.8) | 2.1 (0.7) | 0.88 | 2.2 (0.6) | 0.40 | 0.38 |
| Vital signs | ||||||
| Heart rate (beat per min) | 86.7 (13.0) | 88.1 (13.1) | 0.83 | 109.1 (22.4) | 0.83 | 0.01 |
| Respiratory rate (breath per min) | 18.7 (2.4) | 19.3 (1.1) | 0.49 | 20.1 (3.1) | 0.49 | 0.38 |
| Temperature (°F) | 98.5 (0.3) | 98.1 (1.3) | 0.41 | 98.5 (1.1) | 0.41 | 0.34 |
| Oxygen % | 99.5 (0.8) | 99.5 (1.2) | 1.00 | 98.3 (2.4) | 1.00 | 0.13 |
| Biochemistry | ||||||
| Glucose (mg/dL) | 377 (178) | 313 (75.6) | 0.29 | 546.5 (252.2) | 0.14 | 0.00 |
| Sodium (mmol/L) | 136.5 (2) | 134.1 (3.4) | 0.14 | 134.5 (4.3) | 0.29 | 0.76 |
| Potassium (mmol/L) | 4.2 (0.2) | 4.2 (0.3) | 0.53 | 4.5 (0.8) | 0.30 | 0.33 |
| Chloride (mmol/L) | 99.7 (2.2) | 97.8 (4.0) | 0.32 | 97.1 (6.7) | 0.37 | 0.75 |
| Bicarbonate (CO2) (mmol/L) | 27.2 (0.2) | 22.4 (2.6) | 0.054 | 16.0 (8.1) | 0.01 | 0.04 |
| BUN (mg/dL) | 9.2 (1.5) | 11.9 (3.4) | 0.08 | 15.1 (7.8) | 0.08 | 0.21 |
| Creatinine (mg/dL) | 0.9 (0.4) | 0.8 (0.2) | 0.51 | 1.2 (0.7) | 0.20 | 0.02 |
| Calcium (mg/dL) | 9.5 (0.6) | 9.9 (0.5) | 0.11 | 9.8 (2.2) | 0.68 | 0.91 |
| Phosphorus (mg/dL) | 3.5 (1.2) | 4.6 (0.7) | 0.10 | 4.6 (1.6) | 0.23 | 0.92 |
| Magnesium (mg/dL) | 1.9 (0.2) | 2.0 (0.2) | 0.81 | 2.2 (0.6) | 0.32 | 0.38 |
| HbA1c (%) | 13.0 (2.0) | 11.6 (2.6) | 0.28 | 12.3 (2.1) | 0.45 | 0.45 |
| Serum osmolality (mOsm/kg) | 305.1 (16) | 292.6 (9.3) | 0.046 | 318.0 (46) | 0.51 | 0.08 |
| Beta-hydroxybutyrate (BHOB) (mmol/L) | 1.1 (0.7) | 2.4 (2.5) | 0.40 | 4.1 (3.5) | 0.16 | 0.26 |
| Urine ketone | 60.0 (28) | 40.0 (38.7) | 1.00 | 55.7 (31.4) | 1.00 | 1.00 |
| Venous blood gas | ||||||
| pCO2 (mmHg) | 44.6 (10.9) | 42.1 (6.9) | 0.59 | 37.3 (10.0) | 0.16 | 0.18 |
| Bicarbonate (HCO3) (mmol/L) | 23.5 (8.1) | 22.4 (3.6) | 0.71 | 17.4 (7.8) | 0.10 | 0.06 |
| pH | 7.26 (0.2) | 7.35 (0.05) | 0.08 | 7.23 (0.2) | 0.78 | 0.04 |
Length of PICU stay (days)∗ was calculated only among cases who were managed in PICU. Length of floor stay (days)∗∗ was calculated only among cases who were managed on the floor. Duration of DKA (hours)∗∗∗ was calculated only among cases admitted with DKA.
4. Discussion
Consistent with the previous reports in the U.S. and international studies, we also observed a dramatic increase in hospitalization rates for new-onset DM in both type 1 and type 2 groups [5, 9]. Previous reports described that the diabetes incidence among patients age < 18 years was significantly higher among those with SARS-CoV-2 than among those without SARS-CoV-2 [5, 9]; however, we did not find a direct association of increased rates of DM with SARS-CoV-2 infection since we only had 3 active cases of SARS-CoV-2 detected via PCR upon admission. One limitation to our study is the relatively small sample size (referrals to our hospital were also limited by COVID-19-only designation) and limited to our center which only involves two hospitals. Additionally, we did not systematically investigate IgG antibody levels (to indicate recent, not active infection) or determine whether patients had recent symptoms suggesting prior SARS-CoV-2 infection.
In our study, the hospitalization rates of new-onset DM with DKA increased from 0.24 (95% CI 0.1-0.6) and 0.19 (95% CI 0.1-0.5) to 0.96 (95% CI 0.5-1.6) (p = 0.0014), similar to the previous reports [5, 6, 9, 17, 23, 31]. Similar to reports from the U.K. and Germany, we observed an increase of DKA severity (by lower serum bicarbonate levels) in 2020 compared to 2018 [5, 9, 23], particularly in T1DM. In T2DM, the degree of dehydration and hyperglycemia appeared worse in 2020, probably due to the increased number of patients presenting with mixed HHS/DKA, thus leading to longer time in DKA and recovery time in the PICU.
A previous study showed that DKA severity is worse among Black patients compared to others; however in our study, we had a majority of Black patients and were not able to do comparisons by race [6].
We did not find a significant increase of T1DM admission rates across 3 years. Our results are similar with the report by Marks et al. but is not in agreement with Unsworth et al. who observed an increase of T1DM cases in the U.K. [9]. These differences may be explained by a different demographic makeup of our study [6, 9]. Similar to other reports, we observed an increase of hospitalizations of new-onset T1DM [4, 6, 7, 9] and increased rates of patients hospitalized with DKA and new-onset T1DM [4, 23]. An increase in hospitalization rates for T2DM overall and new-onset T2DM is similar with other studies [6, 7, 12, 17]. We are unable to conclude whether there was a change in severity of DKA for T2DM during the COVID-19 pandemic, given that the numbers are quite small. We similarly found increased number of hospitalized patients with HHS/mixed picture, which is similar to other reports of increased severe DKA with hyperosmolarity during the COVID-19 pandemic in the U.S. [11, 12, 17].
We did not specifically look at longitudinal changes in BMI in the same cohort, although the observed BMI z-scores based on our data was not different in our study from prepandemic to pandemic years. In another study examining the changes in BMI z-score in pediatric patients in municipal hospitals across NYC, there was an increase in annual BMI z-score from 2018 to 2019 by 3.1% and from 2019 to 2020 by 34.3% in the general pediatric population [13] which helps lend suspicion that perhaps the observed increased hospitalizations of T2DM or new-onset T2DM may be due to weight changes.
Major strengths of our study are worth mentioning. Our cases were reviewed, and diagnosis and classification were based on ADA and ISPAD criteria. We examined a wide range of sociodemographic, clinical, and biochemical characteristics. Our sample was drawn from two hospitals in serving Central Brooklyn with a unique population of mostly Blacks and Caribbean-Americans. Admission rates for patients with diabetes were adjusted for overall decreases in pediatric cases which were affected by citywide shutdown as well as SUNY Downstate redesignation as COVID-19-only, rather than counting number of cases only. However, it is worth mentioning that we were unable to take into account changes in who was not coming into the Downstate ER and where they are receiving care and whether they stayed home or presented to another hospital in Brooklyn. This limitation is a minor cause of concern since the overall number of admissions for patients with diabetes and its breakdown shown in Table 1 shows the absolute number of patients increasing in conjunction with the calculated rates of hospitalizations increasing.
Additional limitation to this study was that we were not able to examine precise weight gain before admission for hospitalized patients, especially for new-onset T2DM. Initially, we were expecting to find that rapid or recent significant weight gain during the pandemic would be a risk factor for developing T2DM. Our sample was relatively homogeneous, with no opportunity to examine variation of admission rates by race and ethnicity.
5. Conclusion
Our urban academic medical center located in Central Brooklyn serves a majority who are Black. As far as we know, this is the first study investigating pediatric diabetes cases admitted in Central Brooklyn during the first major wave of the pandemic. Overall, hospitalization rates in children with T2DM and in new-onset T1DM and T2DM increased, despite the overall pediatric admissions declining in 2020 during the citywide shutdown. Patients with new-onset T1DM also presented with DKA more often than what we had seen prepandemic. Whether the shutdown affected patient's perception of their symptoms or another reason leading to delayed care or change in access to care remains to be seen. Active SARS-CoV-2 infection did not appear to be a risk factor for those admitted for diabetes. Larger-scale multicenter studies are needed to elucidate the reason for this observed increase in hospitalization rates of pediatric patients with diabetes mellitus.
Data Availability
The original data used to support the findings of this study is available from the corresponding author upon request.
Disclosure
This work was performed as part of the Pediatric Endocrinology Fellowship Program at SUNY Downstate Health Sciences University, not grant funded. This study was presented as an abstract at the 2022 Pediatric Endocrine Society (PES) Annual Meeting.
Conflicts of Interest
The authors declare that they have no conflicts of interest.
References
- 1.NYC. COVID-19: Data. NYC Health . GitHub, Inc.; 2022. https://www1.nyc.gov/site/doh/covid/covid-19-data.page . [Google Scholar]
- 2.CDC. Coronavirus disease 2019 in children-United States, February 12-April 2, 2020. MMWR. Morbidity and Mortality Weekly Report . 2020;69(14):422–426. doi: 10.15585/mmwr.mm6914e4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Divers J., Mayer-Davis E. J., Lawrence J. M., et al. Trends in incidence of type 1 and type 2 diabetes among youths-selected counties and Indian reservations, United States, 2002-2015. MMWR. Morbidity and Mortality Weekly Report . 2020;69(6):161–165. doi: 10.15585/mmwr.mm6906a3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Alfayez O. M., Aldmasi K. S., Alruwais N. H., et al. Incidence of diabetic ketoacidosis among pediatrics with type 1 diabetes prior to and during COVID-19 pandemic: a meta-analysis of observational studies. Frontiers in Endocrinology . 2022;13, article 856958 doi: 10.3389/fendo.2022.856958. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Barrett C. E., Koyama A. K., Alvarez P., et al. Risk for newly diagnosed diabetes >30 days after SARS-CoV-2 infection among persons aged <18 years — United States, March 1, 2020-June 28, 2021. MMWR. Morbidity and Mortality Weekly Report . 2022;71(2):59–65. doi: 10.15585/mmwr.mm7102e2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Marks B. E., Khilnani A., Meyers A., et al. Increase in the diagnosis and severity of presentation of pediatric type 1 and type 2 diabetes during the COVID-19 pandemic. Hormone Research in Pædiatrics . 2022;94(7-8):275–284. doi: 10.1159/000519797. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Modarelli R., Sarah S., Ramaker M. E., Bolobiongo M., Benjamin R., Gumus Balikcioglu P. Pediatric diabetes on the rise: trends in incident diabetes during the COVID-19 pandemic. Journal of the Endocrine Society . 2022;6(4) doi: 10.1210/jendso/bvac024. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Tittel S. R., Rosenbauer J., Kamrath C., et al. Did the COVID-19 lockdown affect the incidence of pediatric type 1 diabetes in Germany? Diabetes Care . 2020;43(11):e172–e173. doi: 10.2337/dc20-1633. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Unsworth R., Wallace S., Oliver N. S., et al. New-onset type 1 diabetes in children during COVID-19: multicenter regional findings in the U.K. Diabetes Care . 2020;43(11):e170–e171. doi: 10.2337/dc20-1551. [DOI] [PubMed] [Google Scholar]
- 10.Loh C., Weihe P., Kuplin N., Placzek K., Weihrauch-Blüher S. Diabetic ketoacidosis in pediatric patients with type 1- and type 2 diabetes during the COVID-19 pandemic. Metabolism . 2021;122, article 154842 doi: 10.1016/j.metabol.2021.154842. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Neyman A., Nabhan Z., Woerner S., Hannon T. Pediatric type 2 diabetes presentation during the COVID-19 pandemic. Clinical Pediatrics . 2021;61(2):133–136. doi: 10.1177/00099228211064030. [DOI] [PubMed] [Google Scholar]
- 12.Magge S. N., Wolf R. M., Pyle L., et al. The coronavirus disease 2019 pandemic is associated with a substantial rise in frequency and severity of presentation of youth-onset type 2 diabetes. The Journal of Pediatrics . 2022;251:51–59.e2. doi: 10.1016/j.jpeds.2022.08.010. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Miller A., Bochner R., Sohler N., et al. Modified body mass index z-scores in children in New York City during the COVID-19 pandemic. Pediatric Obesity . 2022;17(11, article e12958) doi: 10.1111/ijpo.12958. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Tanskey L. A., Goldberg J. P., Chui K., Must A., Sacheck J. M. Accelerated summer weight gain in a low-income, ethnically diverse sample of elementary school children in Massachusetts. Childhood Obesity . 2019;15(4):244–253. doi: 10.1089/chi.2017.0228. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Weaver R. G., Hunt E. T., Armstrong B., et al. COVID-19 leads to accelerated increases in children's BMI z-score gain: an interrupted time-series study. American Journal of Preventive Medicine . 2021;61(4):e161–e169. doi: 10.1016/j.amepre.2021.04.007. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Woolford S. J., Sidell M., Li X., et al. Changes in body mass index among children and adolescents during the COVID-19 pandemic. JAMA . 2021;326(14):1434–1436. doi: 10.1001/jama.2021.15036. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Chao L. C., Vidmar A. P., Georgia S. Spike in diabetic ketoacidosis rates in pediatric type 2 diabetes during the COVID-19 pandemic. Diabetes Care . 2021;44(6):1451–1453. doi: 10.2337/dc20-2733. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Ghosal S., Arora B., Dutta K., Ghosh A., Sinha B., Misra A. Increase in the risk of type 2 diabetes during lockdown for the COVID19 pandemic in India: a cohort analysis. Diabetes and Metabolic Syndrome: Clinical Research and Reviews . 2020;14(5):949–952. doi: 10.1016/j.dsx.2020.06.020. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Han M., Ma K., Wang X., et al. Immunological characteristics in type 2 diabetes mellitus among COVID-19 patients. Frontiers in Endocrinology . 2021;12, article 596518 doi: 10.3389/fendo.2021.596518. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Dilek S., Gürbüz F., Turan İ., Celiloğlu C., Yüksel B. Changes in the presentation of newly diagnosed type 1 diabetes in children during the COVID-19 pandemic in a tertiary center in southern Turkey. Journal of Pediatric Endocrinology & Metabolism . 2021;34(10):1303–1309. doi: 10.1515/jpem-2021-0287. [DOI] [PubMed] [Google Scholar]
- 21.Ebekozien O. A., Noor N., Gallagher M. P., Alonso G. T. Type 1 diabetes and COVID-19: preliminary findings from a multicenter surveillance study in the U.S. Diabetes Care . 2020;43(8):e83–e85. doi: 10.2337/dc20-1088. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Ho J., Rosolowsky E., Pacaud D., et al. Diabetic ketoacidosis at type 1 diabetes diagnosis in children during the COVID-19 pandemic. Pediatric Diabetes . 2021;22(4):552–557. doi: 10.1111/pedi.13205. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Kamrath C., Rosenbauer J., Eckert A. J., et al. Incidence of COVID-19 and risk of diabetic ketoacidosis in new-onset type 1 diabetes. Pediatrics . 2021;148(3) doi: 10.1542/peds.2021-050856. [DOI] [PubMed] [Google Scholar]
- 24.McCluskey C. K., Zee-Cheng J. E., Klein M. J., et al. The temporal relationship between local school closure and increased incidence of pediatric diabetic ketoacidosis. Frontiers in Pediatrics . 2022;10, article 812265 doi: 10.3389/fped.2022.812265. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Rabbone I., Schiaffini R., Cherubini V., et al. Has COVID-19 delayed the diagnosis and worsened the presentation of type 1 diabetes in children? Diabetes Care . 2020;43(11):2870–2872. doi: 10.2337/dc20-1321. [DOI] [PubMed] [Google Scholar]
- 26.Drobnjak M. Keeping Track of New York City’s Children: 2022 . NY: Citizens’ Committee for Children of New York, Inc.: Consolidated Color Press; 2022. [Google Scholar]
- 27.Lampasona V., Petrone A., Tiberti C., et al. Zinc transporter 8 antibodies complement GAD and IA-2 antibodies in the identification and characterization of adult-onset autoimmune diabetes: non insulin requiring autoimmune diabetes (NIRAD) 4. Diabetes Care . 2010;33(1):104–108. doi: 10.2337/dc08-2305. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.American Diabetes Association. 2. Classification and Diagnosis of Diabetes: Standards of medical care in diabetes-2021. Diabetes Care . 2021;44(Supplement 1):S15–s33. doi: 10.2337/dc21-S002. [DOI] [PubMed] [Google Scholar]
- 29.Wolfsdorf J. I., Glaser N., Agus M., et al. ISPAD clinical practice consensus guidelines 2018: diabetic ketoacidosis and the hyperglycemic hyperosmolar state. Pediatric Diabetes . 2018;19(Suppl 27):155–177. doi: 10.1111/pedi.12701. [DOI] [PubMed] [Google Scholar]
- 30.Hardeo Sahai A. K. Statistics in epidemiology: methods, techniques, and applications . Boca Raton, FL: CRC Press; 1996. [Google Scholar]
- 31.Al-Abdulrazzaq D., Alkandari A., Alhusaini F., et al. Higher rates of diabetic ketoacidosis and admission to the paediatric intensive care unit among newly diagnosed children with type 1 diabetes in Kuwait during the COVID-19 pandemic. Diabetes/Metabolism Research and Reviews . 2022;38(3, article e3506) doi: 10.1002/dmrr.3506. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
The original data used to support the findings of this study is available from the corresponding author upon request.